Invitae
360Dx Top 30 Falls 10 Percent in September
Of the 30 companies in the index, every firm saw its share price decline last month. The decline follows a narrower loss in August.
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
The Invitae Common Hereditary Cancers Panel is the first test of its kind to obtain FDA marketing authorization, creating an easier pathway for similar tests.
Invitae Warned by NYSE of Noncompliance
The firm is in the midst of a restructuring and the NYSE noncompliance notification results from Invitae's common stock closing below $1 per share for 30 consecutive days.
Invitae Publishes First Validation Data on MRD Assays, Laying Path to Future Clinical Expansion
Premium
The analytical validity study is the first published featuring full performance data for the firm's Personalized Cancer Monitoring technology.
360Dx Top 30 Ticks Down in August
Out of the 30 companies in the index, 21 firms saw their stock prices decrease, while nine saw their share prices go up.
Jun 1, 2023
360Dx Top 30 Drops 6 Percent in May
Apr 3, 2023
360Dx Top 30 Rebounds 2 Percent in March
Jan 3, 2023
360Dx Top 30 Drops 37 Percent in 2022
Sep 1, 2022